Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30569791 | 0.97 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL761358 | 0.80 | HDAC6 (0.39) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL8737769 | 0.80 | HDAC6 (0.39) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL3716921 | 0.80 | HDAC6 (0.39) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL12096699 | 0.76 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL206709 | 0.76 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL3266659 | 0.76 | CTSD (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL21278220 | 0.76 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL13286079 | 0.76 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL432112 | 0.76 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119546611-A | Preparation process and intermediate of rui Lu Geli | 台湾神隆股份有限公司 | 2025-02-28 | — | — | CN | claimed |
| US-20230357267-A1 | PROCESS FOR PREPARING RELUGOLIX AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2023-11-09 | — | — | US | claimed |
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| US-12403144-B2 | HECT E3 ligase inhibitors and uses thereof | IFOM —FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2025-09-02 | — | — | US | disclosed |
| US-20250235547-A1 | ANTIBODY-DRUG CONJUGATE | UBE CORPORATION (JP) | 2025-07-24 | — | — | US | disclosed |
| WO-2025128873-A1 | HETEROCYCLIC PYRIDINONE COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250170267-A1 | ANTIBODY-DRUG CONJUGATE PRECURSOR AND INTERMEDIATE FOR SYNTHESIS THEREOF | UBE CORPORATION (JP) | 2025-05-29 | — | — | US | disclosed |
| EP-4541796-A1 | EXATECAN DERIVATIVES AND USE THEREOF | Hangzhou Adcoris Biopharma Co., Ltd (CN) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025056066-A1 | EXATECAN HYDROXYLAMINE DERIVATIVE AND USE THEREOF | 杭州爱科瑞思生物医药有限公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-119546611-A | Preparation process and intermediate of rui Lu Geli | 台湾神隆股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20080200445-A1 | Use in treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, inhibitors of Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes; 4-imidazolidinone, 5-(3'-chloro[1,1'-biphenyl]-3-yl)-5-cyclopropyl-2-imino-3-(2,2,2-trifluoroethyl)-, for example | SCHERING CORPORATION & PHARMACOPEIA DRUG DISCOVERY, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2008098056-A2 | HIGH RELAXIVITY CHELATES | EPIX PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008083191-A2 | RADIOFLUORINATION METHODS | GE HEALTHCARE AS (NO) | 2008-07-10 | — | — | WO | disclosed |
| US-20070281865-A1 | MULTI-FUNCTIONAL SPACER FOR GLYCANS | SCRIPPS RESEARCH INSTITUTE, THE | 2007-12-06 | — | — | US | disclosed |
| US-20070281865-A1 | MULTI-FUNCTIONAL SPACER FOR GLYCANS | SCRIPPS RESEARCH INSTITUTE, THE | 2007-12-06 | — | — | US | disclosed |
| EP-1838304-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006065277-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060111370-A1 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION | 2006-05-25 | — | — | US | disclosed |
| US-4091105-A | 2-Imino-3-aminothiazolidines and indoleamine-N-methyltransferase inhibition | MERCK & CO., INC. (US) | 1978-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | HDAC6 3664/4885HDAC1 849/4885HDAC2 1199/4885 |
| US-20060111370-A1 | Heterocyclic aspartyl protease inhibitors | CHRM1, CHRM2, PRSS1 | HDAC6 2138/4885HDAC1 969/4885HDAC2 1666/4885 |
| US-12403144-B2 | HECT E3 ligase inhibitors and uses thereof | NEDD4, ITCH, UBE3A | HDAC6 453/4885HDAC1 929/4885HDAC2 2791/4885 |
| US-20230357267-A1 | PROCESS FOR PREPARING RELUGOLIX AND INTERMEDIATES THEREOF | PRMT8, PRMT7, PRMT1 | HDAC6 924/4885HDAC1 841/4885HDAC2 1873/4885 |
| US-20080200445-A1 | Use in treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, inhibitors of Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes; 4-imidazolidinone, 5-(3'-chloro[1,1'-biphenyl]-3-yl)-5-cyclopropyl-2-imino-3-(2,2,2-trifluoroethyl)-, for example | CTSZ, CTSL, PRSS1 | HDAC6 1566/4885HDAC1 1455/4885HDAC2 2015/4885 |
| US-20250235547-A1 | ANTIBODY-DRUG CONJUGATE | LDHB, LDHA, DLST | HDAC6 160/4885HDAC1 566/4885HDAC2 972/4885 |
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | AURKB, CDK9, AURKA | HDAC6 104/4885HDAC1 94/4885HDAC2 329/4885 |
| US-20250170267-A1 | ANTIBODY-DRUG CONJUGATE PRECURSOR AND INTERMEDIATE FOR SYNTHESIS THEREOF | DLST, LANCL1, DDOST | HDAC6 114/4885HDAC1 508/4885HDAC2 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.